Literature DB >> 18090576

Platinum resistance related to a functional NER pathway.

Rafael Rosell1, Pedro Mendez, Dolores Isla, Miquel Taron.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18090576     DOI： 10.1097/JTO.0b013e31815ba2a1

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  9 in total

Review 1.  Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.

Authors:  Spyridon P Basourakos; Likun Li; Ana M Aparicio; Paul G Corn; Jeri Kim; Timothy C Thompson
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

2.  DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

Authors:  Li-E Wang; Ming Yin; Qiong Dong; David J Stewart; Kelly W Merriman; Christopher I Amos; Margaret R Spitz; Qingyi Wei
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

3.  Single nucleotide polymorphisms (SNPs) in non-small cell lung cancer (NSCLC) patients.

Authors:  Rafael Rosell; Jia Wei
Journal:  Oncologist       Date:  2012-09-26

4.  Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer.

Authors:  V H de Almeida; A C de Melo; D D Meira; A C Pires; A Nogueira-Rodrigues; H K Pimenta-Inada; F G Alves; G Moralez; L S Thiago; C G Ferreira; C Sternberg
Journal:  Braz J Med Biol Res       Date:  2017-11-13       Impact factor: 2.590

5.  Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.

Authors:  Li-Ming Tan; Cheng-Feng Qiu; Tao Zhu; Yuan-Xiang Jin; Xi Li; Ji-Ye Yin; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

6.  Organoruthenium Complexes with Benzo-Fused Pyrithiones Overcome Platinum Resistance in Ovarian Cancer Cells.

Authors:  Jerneja Kladnik; James P C Coverdale; Jakob Kljun; Hilke Burmeister; Petra Lippman; Francesca G Ellis; Alan M Jones; Ingo Ott; Isolda Romero-Canelón; Iztok Turel
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

7.  KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients.

Authors:  M Basso; A Strippoli; A Orlandi; M Martini; M A Calegari; G Schinzari; M Di Salvatore; T Cenci; A Cassano; L M Larocca; C Barone
Journal:  Br J Cancer       Date:  2012-11-22       Impact factor: 7.640

8.  ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen.

Authors:  J Wei; Z Zou; X Qian; Y Ding; L Xie; J J Sanchez; Y Zhao; J Feng; Y Ling; Y Liu; L Yu; R Rosell; B Liu
Journal:  Br J Cancer       Date:  2008-03-25       Impact factor: 7.640

9.  ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.

Authors:  Antonia Strippoli; Sabrina Rossi; Maurizio Martini; Michele Basso; Ettore D'Argento; Giovanni Schinzari; Rosalba Barile; Alessandra Cassano; Carlo Barone
Journal:  Oncotarget       Date:  2016-06-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.